Analysis of Osteoimmune Interactions Linking Inflammation and Bone Destruction in Aggressive Periodontitis (PAG)

February 6, 2018 updated by: Centre Hospitalier Universitaire de Nice
Periodontitis are inflammatory diseases characterized by the destruction of the tooth-supporting bone due to increased bone resorption by osteoclasts (OCLs). Two forms are described: chronic periodontitis (CP) and aggressive periodontitis (AP) that differ by the severity and rapidity of bone loss, much more important for AP than CP. In both forms, the link with uncontrolled activation of the immune system is largely admitted. Despite the physiopathology of CP is fairly well studied, very few data are available regarding AP. The investigators aim is to understand the severity of AP by analyzing the proportion and action of immune and mesnchymal cells potentially involved in bone destruction, on biopsies of periodontal granulation tissue (surgical waste) and blood. Three groups of 20 patients will be included: affected with AP, CP or controls (necessitating an extraction of wisdom teeth).

Study Overview

Status

Terminated

Intervention / Treatment

Detailed Description

Context: Periodontitis are inflammatory diseases affecting the periodontium and characterized by the destruction of the tooth-supporting bone due to increased bone resorption by osteoclasts (OCLs). Two forms are described: chronic periodontitis (CP) and aggressive periodontitis (AP) that differ by the severity and rapidity of bone loss, much more important for AP than CP. In both forms, the link with uncontrolled activation of the immune system is largely admitted. But despite the physiopathology of CP is fairly well studied, very few data are available regarding AP. Based on the investigators previous studies, their hypothesis to explain this severity is the existence of a vicious circle involving immune cells, mesenchymal cells and OCLs, that would maintain and amplify inflammation and bone loss.

Study: this is a transversal, interventional and single-center study. It includes 3 groups of 20 patients: affected with AP, CP or controls (necessitating an extraction of wisdom teeth).

Aims: the investigators will compare the proportion of immune and mesenchymal cells in the 3 groups of patients to identify the populations potentially involved in bone destruction. The investigators will compare in vitro their capacity to induce OCL differentiation in order to determine their role in bone loss. The investigators will also compare the capacity of OCLs and mesenchymal cells to activate T cells, in order to determine their role in inflammation.

Methodology: patients will be recruited in the department of periodontology, CHU of Nice. After signing the informed consent, a biopsy of periodontal granulation tissue (surgical waste) will be collected during the usual treatment of these diseases, as well as a blood sample. Then, patients will leave the study. Cells from the biopsies will be analyzed by flow cytometry to determine the proportion of lymphocytic, monocytic and mesenchymal cells. In vitro, their capacity to induce OCL differentiation or to activate T cells will be determined. From the blood samples, OCLs will be generated to study their capacity to activate T cells.

Chronology of consultations and examinations: 3 visits are planned: (1) a routine visit corresponding to the usual treatment of the patient during which it is proposed to participate in the study, (2) a visit to obtaining consent, clinical examination, criteria verification and (3) a visit corresponding to the usual treatment in which will be collected tissue biopsies and blood.

Study Type

Interventional

Enrollment (Actual)

8

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Nice, France, 06000
        • Odontology Department, Nice Unversity Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

  • Inclusion criterias for agressive periodontits

    • Young patients not suffering of any médical conditions
    • Small amount of calculus detected
    • Pocket depth >5mm
    • Alveolar Bone loss >50%
  • Inclusion criterias for chronic periodontitis

    • Evident presence of calculus above or under the gingiva
    • Pocket depth >5mm
  • Inclusion criterias for control patients :

    • Young patients in need of impacted wisdom teeth removal
    • And not suffering of chronic or agressive periodontitis
  • Exclusion criterias :

    • Patients with blood disorder
    • Patients presenting with liver, kidney, or vascular disorder, and /or psychiatric disorder
    • Patients who have allergies
    • Patients taking biphosphonates, anticoagulant drugs, or anticonvulsivant
    • Patients who have had a cancer of the mouth, and/or treated by radiotherapy
    • Patients who have taken anti-inflammatory drugs, and/or anti-cancer drugs, and/or immuno-suppresive drugs in the past 6 months
    • Patients who have had a periodontal treatment in the past 12 months
    • Pregnant Women
    • Patients juged difficult to follow by the investigator
    • Vulnerable patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: chronic periodontitis
biopsy of periodontal granulation tissue (surgical waste)

These populations will be identified by different combinations of antibodies to identify:

  • T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).
  • Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)
  • Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)
Other Names:
  • proportion of lymphocytes, myeloid and mesenchymal populations in the samples, as determined by flow cytometry.
Other: aggressive periodontitis (AP)
biopsy of periodontal granulation tissue (surgical waste)

These populations will be identified by different combinations of antibodies to identify:

  • T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).
  • Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)
  • Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)
Other Names:
  • proportion of lymphocytes, myeloid and mesenchymal populations in the samples, as determined by flow cytometry.
Other: controls
necessitating an extraction of wisdom teeth

These populations will be identified by different combinations of antibodies to identify:

  • T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).
  • Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)
  • Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)
Other Names:
  • proportion of lymphocytes, myeloid and mesenchymal populations in the samples, as determined by flow cytometry.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
proportion of lymphocytes, myeloid and mesenchymal populations in the samples
Time Frame: At the surgery time
determined by flow cytometry
At the surgery time

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jérôme SURMENIAN, MD, Odontology Department, NIce University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2013

Primary Completion (Actual)

December 1, 2017

Study Completion (Actual)

December 1, 2017

Study Registration Dates

First Submitted

November 15, 2013

First Submitted That Met QC Criteria

November 20, 2013

First Posted (Estimate)

November 25, 2013

Study Record Updates

Last Update Posted (Actual)

February 7, 2018

Last Update Submitted That Met QC Criteria

February 6, 2018

Last Verified

February 1, 2018

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aggressive Periodontitis

Clinical Trials on flow cytometry

Subscribe